Javascript must be enabled to continue!
Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) inEscherichia coli
View through CrossRef
AbstractThe human epidermal growth factor receptor (HER) family plays an important role in cell growth and signaling and alteration of its function has been demonstrated in many different kinds of cancer. Receptor dimerization is necessary for the HER signal transduction pathway and tyrosine kinase activity. Recently, several monoclonal antibodies have been developed to directly interfere with ligand–HER receptor binding and receptor dimerization. A single chain variable fragment (ScFv) is a valuable alternative to an intact antibody. This report describes the production and purification of an ScFv specific for domain II of the HER2 receptor in Escherichia coli BL21 (DE3) cytoplasm. The majority of expressed of anti-her2his-ScFv protein was produced as inclusion bodies. A Ni-NTA affinity column was used to purify the anti-her2his-ScFv protein. The molecular weight of anti-her2his-ScFv protein was estimated to be approximately 27 kDa, as confirmed by SDS-PAGE and Western blotting assay. The anti-her2his-ScFv showed near 95 % purity and reached a yield of approximately 29 mg/l in flask fermentation. The purified anti-her2his-ScFv showed its biological activity by binding to HER2 receptor on the surface of BT-474 cells. This ScFv may be a potential pharmaceutical candidate for targeting tumour cells overexpressing HER2 receptor.
Oxford University Press (OUP)
Title: Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) inEscherichia coli
Description:
AbstractThe human epidermal growth factor receptor (HER) family plays an important role in cell growth and signaling and alteration of its function has been demonstrated in many different kinds of cancer.
Receptor dimerization is necessary for the HER signal transduction pathway and tyrosine kinase activity.
Recently, several monoclonal antibodies have been developed to directly interfere with ligand–HER receptor binding and receptor dimerization.
A single chain variable fragment (ScFv) is a valuable alternative to an intact antibody.
This report describes the production and purification of an ScFv specific for domain II of the HER2 receptor in Escherichia coli BL21 (DE3) cytoplasm.
The majority of expressed of anti-her2his-ScFv protein was produced as inclusion bodies.
A Ni-NTA affinity column was used to purify the anti-her2his-ScFv protein.
The molecular weight of anti-her2his-ScFv protein was estimated to be approximately 27 kDa, as confirmed by SDS-PAGE and Western blotting assay.
The anti-her2his-ScFv showed near 95 % purity and reached a yield of approximately 29 mg/l in flask fermentation.
The purified anti-her2his-ScFv showed its biological activity by binding to HER2 receptor on the surface of BT-474 cells.
This ScFv may be a potential pharmaceutical candidate for targeting tumour cells overexpressing HER2 receptor.
Related Results
HER2 expression dynamics and prognostic significance in the treatment of gastric cancer.
HER2 expression dynamics and prognostic significance in the treatment of gastric cancer.
4025
Background:
The human epidermal growth factor receptor 2 (HER2) expression undergoes changes during the treatment of gastric canc...
Abstract P4-13-22: Successful targeting HER2 in heavily pretreated HER2-negative metastatic breast cancer patients presenting with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells
Abstract P4-13-22: Successful targeting HER2 in heavily pretreated HER2-negative metastatic breast cancer patients presenting with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells
Abstract
Background: A considerable proportion of patients (pts) with HER2-negative (HER2-) metastatic breast cancer (MBC) present with elevated serum levels of the ...
Abstract P4-15-07: HER2 positive (HER2/CEP17 ratio≥2.0) invasive mammary carcinomas with average <4.0 HER2 and <2.0 CEP17 signals/cell: Clinicopathologic features, correlation with HER2 immunohistochemistry and response to neoadjuvant chemot
Abstract P4-15-07: HER2 positive (HER2/CEP17 ratio≥2.0) invasive mammary carcinomas with average <4.0 HER2 and <2.0 CEP17 signals/cell: Clinicopathologic features, correlation with HER2 immunohistochemistry and response to neoadjuvant chemot
Abstract
Background: ASCO/CAP guidelines for the determination of HER2 amplification have recently been revised in an attempt to clarify which patients will benefit ...
HER2-positive Apocrine Carcinoma of the Breast: A population-based Analysis of Treatment and Outcome
HER2-positive Apocrine Carcinoma of the Breast: A population-based Analysis of Treatment and Outcome
Abstract
Aims
Apocrine carcinoma of the breast (APO) expresses HER2 in 30-50% of cases. This study explored the clinicopathological features and outcome of HER2+ APO (HER2...
Abstract P4-04-05: circHEACA promotes anti-HER2 drug resistance by HEACA-GRB7/AKT axis in HER2+ breast cancer patients
Abstract P4-04-05: circHEACA promotes anti-HER2 drug resistance by HEACA-GRB7/AKT axis in HER2+ breast cancer patients
Abstract
Background: Some HER2-positive (HER2+) breast cancer patient are resistant to anti-HER2 therapy, and the potential reasons of anti-HER2 drug resistance rema...
Abstract 3331: CD24 promotes HER2 signaling pathways and CD24 inhibition sensitizes anti-HER2 therapy in breast cancer
Abstract 3331: CD24 promotes HER2 signaling pathways and CD24 inhibition sensitizes anti-HER2 therapy in breast cancer
Abstract
Human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancers are treated with HER2-targeted agents such as trastuzumab and lapatinib, which...
Use of multimodal circulating tumor cell assay to detect HER2-ultralow and ER co-expression matched with single-cell chromosomal instability in metastatic breast cancer.
Use of multimodal circulating tumor cell assay to detect HER2-ultralow and ER co-expression matched with single-cell chromosomal instability in metastatic breast cancer.
e13024
Background:
Breast cancer is the second leading cause of cancer-related mortality among US women, with metastatic breast cancer...
Global evolution of HER2-targeted clinical trials across solid tumors: Shifts in tumor representation, biomarker definitions, therapeutic modalities, and geographic leadership.
Global evolution of HER2-targeted clinical trials across solid tumors: Shifts in tumor representation, biomarker definitions, therapeutic modalities, and geographic leadership.
e23085
Background:
HER2 has expanded from a breast-restricted biomarker to a pan-tumor therapeutic tar...

